Answers are grounded in this paper and cite their sources.
Purpose Ki67 is an established biomarker in breast tumors but so far, its role in endometrial cancer biology has not been studied. Therefore, the aim of the current study is to evaluate the association of Ki67 with molecular subgroups, ER status, and FIGO staging. Methods Patients with endometrial cancer were retrospectively included. Ki67 expression was immunohistochemically assessed as the percentage of positive tumor nuclei and categorized as < 10%, 10–20%, and > 20%. Statistical analyses included ANOVA with pairwise comparison, Kruskal–Wallis and Spearman’s rank correlation analyses. Results With a median overall Ki67 expression of 10% (range 1–90%), significant differences between the molecular subgroups were noted with highest Ki67 levels in p53abnormal tumors (32.5%, range 5–90%), followed by POLEmut tumors (25%, range 5–90%), dMMR tumors (13.5%, range 1–70%), and NSMP tumors (7%, range 1–85%). Within the NSMP subgroup, median Ki67 level in the 72 ER positive tumors was significantly lower to the 12 ER negative tumors and/or high-grade histology ( p = 0.005). A positive correlation for Ki67 with International Federation of Gynecology and Obstetrics (FIGO) stage was noted, with an even stronger association observed for the classification from 2023, compared to 2009 (rho = 0.45 vs. 0.41, both p < 0.01). Conclusion Ki67 expression varies significantly across endometrial cancer molecular subgroups and has a strong positive correlation to p53abnormal status, tumors with loss of ER expression, and advanced FIGO stage. Our findings suggest that combining Ki67 and ER status may serve as a valuable biomarker combination for stratification within the NSMP subgroup, supporting future prospective clinical validation.
No takes yet. Share an insight, caveat, or question.
Chelariu-Raicu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: